{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:42:59Z","timestamp":1758591779895,"version":"3.44.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018337","name":"South Asian University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.virol.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T08:11:06Z","timestamp":1658391066000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Edelfosine reactivates latent HIV-1 reservoirs in myeloid cells through activation of NF-\u03baB and AP1 pathway"],"prefix":"10.1016","volume":"574","author":[{"given":"Madhu","family":"Rai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartik","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Khalid","family":"Muhammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-9623","authenticated-orcid":false,"given":"Ritu","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2022.07.008_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091970","article-title":"The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response","volume":"9","author":"Abramowski","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2022.07.008_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.03060","article-title":"Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs","volume":"10","author":"Ait-Ammar","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2022.07.008_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12985-016-0637-9","article-title":"Activation of HIV-1 expression in latently infected CD4+ T cells by the small molecule PKC412","volume":"13","author":"Ao","year":"2016","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2022.07.008_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0166-3542(02)00052-9","article-title":"Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir","volume":"55","author":"Aquaro","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.07.008_bib5","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.virol.2022.07.008_bib6","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1021\/jp802165n","article-title":"Edelfosine is incorporated into rafts and alters their organization","volume":"112","author":"Ausili","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.virol.2022.07.008_bib7","first-page":"720","article-title":"Efficacy of edelfosine lipid nanoparticles in breast cancer cells","volume":"454","author":"Aznar","year":"2013","journal-title":"Int. J. Pharm., Targeted Drug Delivery"},{"key":"10.1016\/j.virol.2022.07.008_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","article-title":"The NF-\u03baB and I\u03baB proteins: new discoveries and insights","volume":"14","author":"Baldwin","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.virol.2022.07.008_bib9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3390\/v6041715","article-title":"HIV-1 latency: an update of molecular mechanisms and therapeutic strategies","volume":"6","author":"Battistini","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2022.07.008_bib10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chom.2016.07.015","article-title":"Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals","volume":"20","author":"Baxter","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2022.07.008_bib11","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1128\/jvi.65.9.4645-4653.1991","article-title":"Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection","volume":"65","author":"Butera","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib12","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1021\/jp401407d","article-title":"Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids","volume":"117","author":"Castro","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.virol.2022.07.008_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/COH.0b013e32834124fd","article-title":"NF-\u03baB\/Rel: agonist and antagonist roles in HIV-1 latency","volume":"6","author":"Chan","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2022.07.008_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.03299-12","article-title":"Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation","author":"Checkley","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib15","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1002\/cpmb.56","article-title":"Using barcoded HIV ensembles (B-HIVE) for single provirus transcriptomics","volume":"122","author":"Chen","year":"2018","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"10.1016\/j.virol.2022.07.008_bib16","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1074\/jbc.M807898200","article-title":"Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells","volume":"284","author":"Contreras","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2022.07.008_bib17","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1128\/JVI.74.15.6790-6799.2000","article-title":"The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1","volume":"74","author":"Coull","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1189\/jlb.0503204","article-title":"The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection","volume":"74","author":"Crowe","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.virol.2022.07.008_bib19","doi-asserted-by":"crossref","first-page":"ofw189","DOI":"10.1093\/ofid\/ofw189","article-title":"Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents","volume":"3","author":"Delagr\u00e8verie","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.virol.2022.07.008_bib20","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jmb.2013.10.033","article-title":"Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all","volume":"426","author":"Desimmie","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2022.07.008_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4690-10-11","article-title":"Cellular and molecular mechanisms involved in the establishment of HIV-1 latency","volume":"10","author":"Donahue","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2022.07.008_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000217391","article-title":"Final evaluation of a phase II study on the effect of edelfosine (an ether lipid) in advanced non-small-cell bronchogenic carcinoma","volume":"15","author":"Drings","year":"1992","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.virol.2022.07.008_bib23","doi-asserted-by":"crossref","DOI":"10.2174\/1871520614666140309230722","article-title":"Edelfosine in membrane environment - the Langmuir monolayer studies","volume":"14","author":"Dynarowicz-Latka","year":"2014","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.virol.2022.07.008_bib24","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1128\/JVI.72.2.1666-1670.1998","article-title":"Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line","volume":"72","author":"Emiliani","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib25","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1128\/JVI.03251-12","article-title":"Targeting I B proteins for HIV latency activation: the role of individual I B and NF- B proteins","volume":"87","author":"Fernandez","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.virol.2022.07.008_bib27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.3313729","article-title":"Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line","volume":"238","author":"Folks","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.virol.2022.07.008_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts","volume":"109","author":"Gajate","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.virol.2022.07.008_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1742-4690-5-51","article-title":"HIV-1 Vif, APOBEC, and intrinsic immunity","volume":"5","author":"Goila-Gaur","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2022.07.008_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007991","article-title":"Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations","volume":"15","author":"Grau-Exp\u00f3sito","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2022.07.008_bib32","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/MCB.22.9.2965-2973.2002","article-title":"Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator tat","volume":"22","author":"He","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.virol.2022.07.008_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/26026","article-title":"Apoptosis of CD8 + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4","volume":"395","author":"Herbein","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.virol.2022.07.008_bib34","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1126\/science.280.5371.1866","article-title":"Toward HIV eradication or remission: the tasks ahead","volume":"280","author":"Ho","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.virol.2022.07.008_bib35","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1073\/pnas.94.11.5826","article-title":"Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid","volume":"94","author":"Huang","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2022.07.008_bib36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2014.05.033","article-title":"Reactivation of latent HIV-1 by new semi-synthetic ingenol esters","author":"Jos\u00e9","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.virol.2022.07.008_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0b013e328340ffbb","article-title":"The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit","volume":"6","author":"Karn","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2022.07.008_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/aid.1990.6.491","article-title":"Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation","volume":"6","author":"Kucera","year":"1990","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.virol.2022.07.008_bib39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAI.0000000000001958","article-title":"Heterogeneous HIV-1 reactivation patterns of Disulfiram and combined Disulfiram+Romidepsin treatments","volume":"80","author":"Kula","year":"2019","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.virol.2022.07.008_bib40","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3390\/v6041837","article-title":"HIV-1 latency in monocytes\/macrophages","volume":"6","author":"Kumar","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2022.07.008_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-4690-7-32","article-title":"Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage","volume":"7","author":"Le Douce","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2022.07.008_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013121","article-title":"Targeting the PI3K\/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds","volume":"5","author":"Lucas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2022.07.008_bib43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/sj.emboj.7601516","article-title":"Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing","volume":"26","author":"Marban","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2022.07.008_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1172\/JCI114981","article-title":"Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients","volume":"87","author":"McElrath","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2022.07.008_bib45","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-08-1654","article-title":"Antitumor Alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice","volume":"15","author":"Mendoza","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.virol.2022.07.008_bib46","article-title":"Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), A proapoptotic agent in tumor cells","author":"Mollinedo","year":"2002","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.virol.2022.07.008_bib47","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2174\/0929867043363703","article-title":"ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of fas\/CD95 death receptor","volume":"11","author":"Mollinedo","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.virol.2022.07.008_bib48","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/1078-0432.CCR-09-2456","article-title":"In vitro and in vivo selective antitumor activity of edelfosine against Mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts","volume":"16","author":"Mollinedo","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.virol.2022.07.008_bib49","doi-asserted-by":"crossref","first-page":"26177","DOI":"10.1074\/jbc.M116.743906","article-title":"Heat shock protein 90 facilitates latent HIV reactivation through maintaining the function of positive transcriptional elongation factor b (p-TEFb) under proteasome inhibition","volume":"291","author":"Pan","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2022.07.008_bib50","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.celrep.2019.10.101","article-title":"Latency-reversing agents induce differential responses in distinct memory CD4 T cell subsets in individuals on antiretroviral therapy","volume":"29","author":"Pardons","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.virol.2022.07.008_bib51","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J. Virol."},{"year":"2016","series-title":"United States Patent: 9265577 - Methods and Systems for Providing Planning and Dispensation of Research And\/or Treatment for Brain Disease","author":"Raghavan","key":"10.1016\/j.virol.2022.07.008_bib52"},{"key":"10.1016\/j.virol.2022.07.008_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32316-2","article-title":"Serum deprivation\/starvation leads to reactivation of HIV-1 in latently infected monocytes via activating ERK\/JNK pathway","volume":"8","author":"Raja","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2022.07.008_bib54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/COH.0000000000000279","article-title":"Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?","volume":"11","author":"Rasmussen","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2022.07.008_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tim.2015.11.003","article-title":"Reversal of latency as part of a cure for HIV-1","volume":"24","author":"Rasmussen","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2022.07.008_bib56","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-17-2994","article-title":"Targeting brain-adaptive cancer stem cells prohibits brain metastatic colonization of triple-negative breast cancer","volume":"78","author":"Ren","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2022.07.008_bib57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-virology-091919-103029","article-title":"The current status of latency reversing agents for HIV-1 remission","volume":"8","author":"Rodari","year":"2021","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib58","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/nm945","article-title":"The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif","volume":"9","author":"Sheehy","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2022.07.008_bib59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tim.2013.02.005","article-title":"Reactivation of latent HIV by histone deacetylase inhibitors","volume":"21","author":"Shirakawa","year":"2013","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2022.07.008_bib60","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni1097","article-title":"Protein kinase C and beyond","volume":"5","author":"Spitaler","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2022.07.008_bib61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev-med-052716-031710","article-title":"Latency reversal agents for HIV-1 cure","volume":"69","author":"Spivak","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.virol.2022.07.008_bib62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1097-2765(03)00353-8","article-title":"HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability","volume":"12","author":"Stopak","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.virol.2022.07.008_bib63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1099\/jgv.0.001205","article-title":"Role of APOBEC3 proteins in proteasome inhibitor-mediated reactivation of latent HIV-1 viruses","volume":"100","author":"Timilsina","year":"2019","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib64","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1038\/sj.emboj.7601928","article-title":"CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency","volume":"26","author":"Tyagi","year":"2007","journal-title":"EMBO J."},{"author":"United States Patent","key":"10.1016\/j.virol.2022.07.008_bib65"},{"key":"10.1016\/j.virol.2022.07.008_bib66","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1074\/jbc.M209622200","article-title":"Exogenous nef protein activates NF-\u03baB, AP-1, and c-jun N-terminal kinase and stimulates HIV transcription in promonocytic cells","volume":"278","author":"Varin","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2022.07.008_bib67","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1038\/s41598-017-07157-0","article-title":"Reactivation of HIV-1 from latency by an ingenol derivative from Euphorbia kansui","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2022.07.008_bib68","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.mam.2010.06.001","article-title":"HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors","volume":"31","author":"Wissing","year":"2010","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.virol.2022.07.008_bib69","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1128\/JVI.06726-11","article-title":"Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-\u03baB activity","volume":"86","author":"Wolschendorf","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib70","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1128\/JVI.02033-10","article-title":"Disulfiram reactivates latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation","volume":"85","author":"Xing","year":"2011","journal-title":"J. Virol."},{"year":"2020","series-title":"Doxorubicin and Edelfosine Combo-Loaded Lipid\u2013Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect against Drug-Resistant Osteosarcoma","author":"Yang","key":"10.1016\/j.virol.2022.07.008_bib71"},{"key":"10.1016\/j.virol.2022.07.008_bib72","doi-asserted-by":"crossref","first-page":"e02110","DOI":"10.1128\/JVI.02110-17","article-title":"Class 1-selective histone deacetylase (HDAC) inhibitors enhance HIV latency reversal while preserving the activity of HDAC isoforms necessary for maximal HIV gene expression","volume":"92","author":"Zaikos","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.07.008_bib73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/164_2019_222","article-title":"Lipids and membrane microdomains: the glycerolipid and alkylphosphocholine class of cancer chemotherapeutic drugs","volume":"259","author":"Zaremberg","year":"2020","journal-title":"Handb. Exp. Pharmacol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222001131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222001131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:57:37Z","timestamp":1758589057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682222001131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":72,"alternative-id":["S0042682222001131"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2022.07.008","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edelfosine reactivates latent HIV-1 reservoirs in myeloid cells through activation of NF-\u03baB and AP1 pathway","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}